Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Treviso – page 55

920 clinical trials in Treviso, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Treviso at a glance
920
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

920 trials in Treviso

Open in trial search

Small cell lung cancer+1

Not recruiting

Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Metastatic renal cell carcinoma

Not recruiting

Study on Pembrolizumab for Patients with Resectable Metastases from Kidney Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Consorzio Oncotech

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Early-Stage Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Ovarian cancer recurrent

Not recruiting

Study of Avutometinib and Defactinib for Patients with Recurrent Low-Grade Serous Ovarian Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avutometinib
  • Sponsor:Verastem Inc.

Rectal cancer

Not recruiting

Study on Capecitabine and Oxaliplatin for Patients with High Risk Rectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Colorectal cancer stage II+1

Not recruiting

Study of Drug Combination Treatment (Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan) Guided by Liquid Biopsy Testing in Patients with Stage III and High-Risk Stage II Colon Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Ornithine transcarbamoylase deficiency

Not recruiting

Study of Avalotcagene Ontaparvovec for Patients Aged 12 and Older with Late-onset Ornithine Transcarbamylase Deficiency

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Ultragenyx Pharmaceutical Inc.

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Colorectal cancer

Not recruiting

Study of Nivolumab, Ipilimumab, Relatlimab, and Daratumumab in Patients with Recurrent and Metastatic Colon Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Bristol Myers Squibb International Corporation

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Extranodal marginal zone B-cell lymphoma (MALT type)

Not recruiting

Study on Chlorambucil and Rituximab for Patients with MALT Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Chlorambucil
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Treviso

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials exploring treatments for Acute Myeloid Leukemia and Lymphomas, including studies on targeted therapies combined with standard chemotherapy. Research focuses on improving treatment outcomes for various blood cancers.

  • Gemtuzumab Ozogamicin for AML
  • Daratumumab for Plasmablastic Lymphoma
  • Follicular Lymphoma Treatment Optimization

Advanced therapeutic approaches aim to enhance minimal residual disease control and patient outcomes.

02 Gynecologic Oncology

Comprehensive research into ovarian cancer treatments, including studies of maintenance therapies and novel drug combinations. Investigations focus on both recurrent and newly diagnosed cases.

  • Olaparib Maintenance Therapy
  • Low-grade Serous Carcinoma Treatment
  • Cervical Cancer Prevention

Studies emphasize personalized treatment approaches based on specific genetic markers and disease characteristics.

03 Respiratory Medicine

Groundbreaking research in lung cancer and severe respiratory conditions, including targeted therapies for specific genetic mutations and innovative treatment combinations.

  • ALK-positive NSCLC Treatment
  • Small Cell Lung Cancer Therapy
  • Severe Asthma Management

Focus on developing personalized treatment strategies for various lung cancer subtypes and respiratory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.